Cardiovascular disease

Questions discussed in this category

Is there any difference in the cardiovascular risk reduction profile of brand name Vascepa versus generic icosapent ethyl for patients with hypertriglyceridemia?

1 Answer available

What is your approach to management of hyperlipidemia in patients taking JAK inhibitors?

1 Answer available

What is your approach to monitoring lipids in patients with rheumatic diseases such as RA and SLE and do you have a lower threshold to start lipid lowering agents compared to the general population?

2 Answers available

Papers discussed in this category

Southern medical journal, 2016-11

Effects of Statin Therapy in Patients with Systemic Lupus Erythematosus.

Annals of the rheumatic diseases, 2011-05

Lupus Atherosclerosis Prevention Study (LAPS).

Atherosclerosis, 2015 Aug 28

Statin reduces mortality and morbidity in systemic lupus erythematosus patients with hyperlipidemia: A nationwide population-based cohort study.

N Engl J Med,

Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis.

Autoimmunity reviews, 2023 Dec 20

Implementation of regulatory guidance for JAK inhibitors use in patients with immune-mediated inflammatory diseases: An international appropriateness study.

The New England journal of medicine, 2019-01-03

Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia.

Related Topics